1
Orphan Designations
0 approved
1
FDA Approvals
Latest: ANDEMBRY (2025)
0
Active Trials
1
Rare Diseases
across 2 areas
2
News (30d)
CSL is a company with 1 orphan drug designation across 1 rare disease, including 1 FDA-approved therapy. 2 news articles in the past 30 days.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| acute myeloid leukemia | chimeric murine/human IgG1 monoclonal antibody to human interleukin-3 receptor alpha chain | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
2
avg importance: 70
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
2
avg importance: 70
0
affecting portfolio